KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Astrana Health (ASTH) Interest & Investment Income (2017 - 2025)

Astrana Health's Interest & Investment Income history spans 9 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 6.78% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $11.4 million, down 28.26%, while the annual FY2024 figure was $14.5 million, 2.11% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $3.5 million at Astrana Health, up from $2.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.6 million in Q4 2023 and bottomed at $46000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $2.3 million (2025), against an average of $2.1 million.
  • The largest annual shift saw Interest & Investment Income tumbled 86.82% in 2022 before it surged 6441.3% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $240000.0 in 2021, then surged by 435.83% to $1.3 million in 2022, then soared by 257.0% to $4.6 million in 2023, then dropped by 29.84% to $3.2 million in 2024, then increased by 9.34% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Interest & Investment Income are $3.5 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025).